Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Type 2 Gaucher Disease”

100 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 100 results

Testing effectiveness (Phase 2)Ended earlyNCT04750239
What this trial is testing

Safety and Clinical Activity of Nivatrotamab in Relapsed/Recurrent Metastatic Small-cell Lung Cancer

Who this might be right for
SCLC
Y-mAbs Therapeutics 3
Not applicableUnknownNCT02120235
What this trial is testing

Investigating Lysosomal Storage Diseases in Minority Groups

Who this might be right for
Lysosomal Storage DisordersGaucher DiseaseFabry Disease+2 more
O & O Alpan LLC 20,000
Early research (Phase 1)Looking for participantsNCT04099797
What this trial is testing

C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)

Who this might be right for
Diffuse Intrinsic Pontine GliomaHigh Grade GliomaEmbryonal Tumor+1 more
Baylor College of Medicine 37
Testing effectiveness (Phase 2)Looking for participantsNCT02992210
What this trial is testing

Study on GD2 Positive Solid Tumors by 4SCAR-GD2

Who this might be right for
Solid Tumor
Shenzhen Geno-Immune Medical Institute 100
Testing effectiveness (Phase 2)UnknownNCT05447494
What this trial is testing

Phase 1/2 Study of CAN103 in Subjects With Gaucher Disease

Who this might be right for
Gaucher Disease, Type 1Gaucher Disease, Type 3
CANbridge (Suzhou) Bio-pharma Co., Ltd. 40
Early research (Phase 1)Study completedNCT01576692
What this trial is testing

Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma

Who this might be right for
Neuroblastoma
St. Jude Children's Research Hospital 34
Early research (Phase 1)Study completedNCT02765243
What this trial is testing

Anti-GD2 4th Generation CART Cells Targeting Refractory and/or Recurrent Neuroblastoma

Who this might be right for
NeuroblastomaEffects of Immunotherapy
Zhujiang Hospital 12
Not applicableStudy completedNCT01418495
What this trial is testing

Pharmacokinetics of Ch14.18 in Younger Patients With High-Risk Neuroblastoma

Who this might be right for
Localized Resectable NeuroblastomaLocalized Unresectable NeuroblastomaNeurotoxicity Syndrome+4 more
National Cancer Institute (NCI) 12
Testing effectiveness (Phase 2)Study completedNCT06438614
What this trial is testing

Naxitamab , Granulocyte Macrophage Colony Stimulating Factor For Patients With Relapsed /Refractory , Soft Tissue or Anti GD2 Immunotherapy Refractory Neuroblastoma

Who this might be right for
Refractory NeuroblastomaSoft Tissue Cancer
Fundació Sant Joan de Déu 47
Testing effectiveness (Phase 2)UnknownNCT03356808
What this trial is testing

Antigen-specific T Cells Against Lung Cancer

Who this might be right for
Lung Cancer
Shenzhen Geno-Immune Medical Institute 20
Large-scale testing (Phase 3)Looking for participantsNCT06669013
What this trial is testing

Chemo-immunotherapy in Patients Under 18 Years of Age With Bone and Soft Tissue Sarcomas

Who this might be right for
Bone SarcomaEmbryonal RhabdomyosarcomaAlveolar Rhabdomyosarcoma
N.N. Petrov National Medical Research Center of Oncology 40
Not applicableUnknownNCT02000310
What this trial is testing

Molecular and Cellular Mechanisms of Lysosomal Storage Diseases

Who this might be right for
Lysosomal Storage Disorders
O & O Alpan LLC 80
Early research (Phase 1)Study completedNCT00877110
What this trial is testing

Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma

Who this might be right for
NeuroblastomaBone Marrow, Sympathetic Nervous System
Memorial Sloan Kettering Cancer Center 71
Early research (Phase 1)Looking for participantsNCT05990751
What this trial is testing

Multi-modular Chimeric Antigen Receptor Targeting GD2 in Neuroblastoma

Who this might be right for
Neuroblastoma
University College, London 12
Early research (Phase 1)Study completedNCT02761915
What this trial is testing

A Phase I Trial of Anti-GD2 T-cells (1RG-CART)

Who this might be right for
Relapsed or Refractory Neuroblastoma
Cancer Research UK 17
Large-scale testing (Phase 3)WithdrawnNCT05815004
What this trial is testing

An Efficacy and Safety Study of AVR-RD-02 Compared to Enzyme Replacement Therapy for Treatment of Gaucher Disease Type 3

Who this might be right for
Gaucher Disease, Type 3
AVROBIO
Early research (Phase 1)Study completedNCT01662804
What this trial is testing

Humanized 3F8 Monoclonal Antibody (Hu3F8) When Combined With Interleukin-2 in Patients With High-Risk Neuroblastoma and GD2-positive Solid Tumors

Who this might be right for
Neuroblastoma
Memorial Sloan Kettering Cancer Center 14
Early research (Phase 1)Looking for participantsNCT05544526
What this trial is testing

CAR T Cells to Target GD2 for DMG

Who this might be right for
Diffuse Midline Glioma, H3 K27M-Mutant
University College, London 12
Testing effectiveness (Phase 2)Study completedNCT00004184
What this trial is testing

Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Melanoma

Who this might be right for
Melanoma (Skin)
University of Alabama at Birmingham 50
Early research (Phase 1)Study completedNCT01460901
What this trial is testing

Study of Donor Derived, Multi-virus-specific, Cytotoxic T-Lymphocytes for Relapsed/Refractory Neuroblastoma

Who this might be right for
Neuroblastoma
Children's Mercy Hospital Kansas City 5
Load More Results